Should we exercise caution with benzodiazepine use in patients with COPD?

European Respiratory Journal

Volumn 44, Issue 2, 2014, Pages 284-286

  Rodriguez Roisin, Robert ^a   Garcia Aymerich, Judith ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; BENZODIAZEPINE; NEUROLEPTIC AGENT; NEUROTRANSMITTER; TRICYCLIC ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE;

ANXIETY; BODY MASS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PRACTICE; COMORBIDITY; DEPRESSION; DISEASE EXACERBATION; DISEASE SEVERITY; DYSPNEA; EDITORIAL; FORCED EXPIRATORY VOLUME; HUMAN; MORTALITY; OXYGEN THERAPY; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; SOCIAL STATUS; SPIROMETRY; FEMALE; MALE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATION DISORDERS;

BENZODIAZEPINES; FEMALE; HUMANS; MALE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATION DISORDERS;

EID: 84905658507     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00071014     Document Type: Editorial

References (21)

1. Shorter E. Benzodiazepines. In: A historical Dictionary of Psychiatry. London, Oxford Universtiy Press, 2005; pp. 41-42.
2. National Institute for Health and Clinical Excellence. Chronic obstructive pulmonary disease. www.nice.org.uk/nicemedia/live/13029/49397/49397. pdf Date last accessed: April 15, 2014. Date last updated: June 2010.
3. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932-946. (Pubitemid 38807371)
4. Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013; 187: 347-365.
5. Ng TP, Niti M, Tan WC, et al. Depressive symptoms and chronic obstructive pulmonary disease: effect on mortality, hospital readmission, symptom burden, functional status, and quality of life. Arch Intern Med 2007; 167: 60-67. (Pubitemid 46072408)
6. Eisner MD, Blanc PD, Yelin EH, et al. Influence of anxiety on health outcomes in COPD. Thorax 2010; 65: 229-234.
7. Hanania NA, Mullerova H, Locantore NW, et al. Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort. Am J Respir Crit Care Med 2011; 183: 604-611.
8. Neuman A, Gunnbjornsdottir M, Tunsater A, et al. Dyspnea in relation to symptoms of anxiety and depression: a prospective population study. Respir Med 2006; 100: 1843-1849. (Pubitemid 44283751)
9. Hill K, Geist RS, Goldstein RS, et al. Anxiety and depression in end-stage COPD. Eur Respir J 2008; 31: 667-677.
10. Maurer J, Rebbapragada V, Borson S, et al. Anxiety and depression in COPD: current understanding, unanswered questions, and research needs. Chest 2008; 134: Suppl., 43S-56S.
11. Coventry PA, Bower P, Keyworth C, et al. The effect of complex interventions on depression and anxiety in chronic obstructive pulmonary disease: systematic review and meta-analysis. PLoS One 2013; 8: e60532.
12. Hilmarsen CW, Wilke S, Engan H, et al. Impact of symptoms of anxiety and depression on COPD Assessment Test scores. Eur Respir J 2014; 43: 898-900.
13. Yohannes AM, Baldwin RC, Connolly MJ. Depression and anxiety in elderly outpatients with chronic obstructive pulmonary disease: prevalence, and validation of the BASDEC screening questionnaire. Int J Geriatr Psychiatry 2000; 15: 1090-1096. (Pubitemid 32093984)
14. Vozoris NT, Fischer HD, Wang X, et al. Benzodiazepine drug use and adverse respiratory outcomes among older adults with COPD. Eur Respir J 2014; 44: 332-340.
15. Ekstrom MP, Bornefalk-Hermansson A, Abernethy AP, et al. Safety of benzodiazepines and opioids in very severe respiratory disease: national prospective study. BMJ 2014; 348: g445.
16. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000; 117: Suppl. 2, 398S-401S. (Pubitemid 30314474)
17. D'Agostino RB Jr, Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998; 17: 2265-2281.
18. Weitzen S, Lapane KL, Toledano AY, et al. Principles for modeling propensity scores in medical research: a systematic literature review. Pharmacoepidemiol Drug Saf 2004; 13: 841-853. (Pubitemid 40003819)
19. Austin PC, Grootendorst P, Anderson GM. A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. Stat Med 1998; 26: 734-753.
20. Balcells E, Gea J, Ferrer J, et al. Factors affecting the relationship between psychological status and quality of life in COPD patients. Health Qual Life Outcomes 2010; 8: 108.
21. Garcia-Aymerich J, Marrades RM, Monso E, et al. Paradoxical results in the study of risk factors of chronic obstructive pulmonary disease (COPD) re-admission. Respir Med 2004; 98: 851-857. (Pubitemid 39069334)